4.7 Meeting Abstract

IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).

Journal

JOURNAL OF CLINICAL ONCOLOGY
Volume 34, Issue 2, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/jco.2016.34.2_suppl.355

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available